Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net ...
This is also the last Karl Brunner Distinguished Lecture for Joël Mesot as ETH President. Joël will soon step down from thi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results